This trial is testing a new drug to see if it is effective and safe in treating seizures in people with a certain type of epilepsy.
1 Primary · 8 Secondary · Reporting Duration: Baseline, Maintenance Period: Week 6 to Week 16
Experimental Treatment
Non-Treatment Group
52 Total Participants · 2 Treatment Groups
Primary Treatment: NBI-921352 · Has Placebo Group · Phase 2
Age 2 - 21 · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: